CME Event: "Injectable Treatments for Migraine"
The Yale School of Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Migraine is a leading cause of disability among Americans. Around 40 million people in the United States have the disease and it is one of the top reasons for emergency room visits. With wait-times increasing among headache specialists and Neurologists, it is vital that non-neurologists and non-headache specialists become comfortable with migraine management. Within 2 years, new migraine preventive treatments have been FDA approved. This new family of medications, called calcitonin gene related peptide (CGRP) medications, are injectable treatments that patients can self-administer monthly. Thus, there is a strong need to teach medical professionals about these new medications, so they can extend their reach and increase the quality of life for patients.
Registration fee* includes continental breakfast, refreshment breaks, and lunch:
- Physicians – $175
- Nurses/PAs/Allied Health Professionals – $100
- Non-Yale Residents/Fellows/Students† – complimentary
- Yale Residents/Fellows/Students† – complimentary
- Yale Neuro Staff – complimentary
- Exhibitor – $3,000